HARBIN, China, Oct. 16 /Xinhua-PRNewswire/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it attended CPhI (Convention of Pharmaceutical Ingredients) Worldwide 2008 in Frankfurt, Germany, from Sept. 30 to Oct. 2.
CPhI Worldwide 2008 is an international exhibition and conference dedicated to the pharmaceutical ingredients industry. At the trade show, China Sky One Medical presented its branded Slim Patch and its Cardiac Arrest Early Examination Kit products. The Slim Patch, which allows a user to lose weight without side effects, is very popular with overseas distributors. The Cardiac Arrest Kit is a newly developed biochemical product used for early stage diagnosis of myocardial infarction. China Sky One Medical's booth at CPhI Worldwide 2008 attracted many visitors who expressed strong interest in the Company's products.
In addition to CPhI Worldwide 2008 in Frankfurt, which attracted over 25,000 attendees, China Sky One Medical will also attend the Supplyside West Show 2008 in Las Vegas, Nevada from Oct. 22 to Oct. 24, 2008, where it will meet with distributors from North and South America; and the China Import and Export Fair in Guangzhou, China, on October 27, 2008, where it will meet with Asian distributors.
"We are excited to attend these trade shows and increase brand name recognition for our products," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "As part of our overall strategy, we will continue to promote our products, improve our sales channels, and stimulate customer demand."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
